Immunoglobulin A Nephropathy Clinical Trials

9 recruiting

Immunoglobulin A Nephropathy Trials at a Glance

12 actively recruiting trials for immunoglobulin a nephropathy are listed on ClinicalTrialsFinder across 6 cities in 38 countries. The largest study group is Phase 2 with 6 trials, with the heaviest enrollment activity in Houston, Beijing, and Seoul. Lead sponsors running immunoglobulin a nephropathy studies include Novartis Pharmaceuticals, Alexion Pharmaceuticals, Inc., and Beijing Mabworks Biotech Co., Ltd..

Browse immunoglobulin a nephropathy trials by phase

Treatments under study

About Immunoglobulin A Nephropathy Clinical Trials

Looking for clinical trials for Immunoglobulin A Nephropathy? There are currently 9 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Immunoglobulin A Nephropathy trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Immunoglobulin A Nephropathy clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 112 of 12 trials

Recruiting
Phase 2

Chinese Adults With Kidney Disease

Immunoglobulin A Nephropathy (IgAN)IC-MPGNComplement 3 Glomerulopathy (C3G)
ADARx Pharmaceuticals, Inc.30 enrolled10 locationsNCT07522099
Recruiting
Phase 3

A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN)

Immunoglobulin A Nephropathy (IgAN)
Biogen454 enrolled228 locationsNCT06935357
Recruiting
Phase 2

Study to Evaluate the Impact of Iptacopan on Top of SOC on Biopsy Changes in Kidneys of Adult Patients With IgAN

Glomerulonephritis, IGAImmunoglobulin A Nephropathy
Novartis Pharmaceuticals20 enrolled18 locationsNCT06797518
Recruiting
Phase 3

Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN)

Immunoglobulin A NephropathyIgAN
Alexion Pharmaceuticals, Inc.510 enrolled267 locationsNCT06291376
Recruiting
Phase 1Phase 2

A Study of MIL116 in Healthy Participants and Patients With IgA Nephropathy.

Immunoglobulin A Nephropathy
Beijing Mabworks Biotech Co., Ltd.130 enrolled1 locationNCT07375758
Recruiting
Phase 2

Study of WAL0921 in Patients With Glomerular Kidney Diseases

Diabetic NephropathiesPrimary Focal Segmental GlomerulosclerosisMinimal Change Disease+2 more
Walden Biosciences96 enrolled50 locationsNCT06466135
Recruiting
Phase 2

A Study to Assess the Effects of Zigakibart on IgA Nephropathy.

Immunoglobulin A Nephropathy (IgAN)
Novartis Pharmaceuticals32 enrolled8 locationsNCT07146906
Recruiting
Phase 3

Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Iptacopan in Pediatric Patients With Primary IgAN

Primary Immunoglobulin A Nephropathy (IgAN)
Novartis Pharmaceuticals31 enrolled15 locationsNCT06994845
Recruiting
Phase 3

Study of Ravulizumab in Pediatric Participants With Primary IgAN

Immunoglobulin A NephropathyIgANIgA Vasculitis+3 more
Alexion Pharmaceuticals, Inc.24 enrolled14 locationsNCT07024563
Recruiting
Phase 2

Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases

Alport SyndromeFocal Segmental GlomerulosclerosisImmunoglobulin A Nephropathy+2 more
Travere Therapeutics, Inc.67 enrolled47 locationsNCT05003986
Recruiting

A Mobile App-Based Study to Evaluate Disease Burden and Treatment Patterns in Immunoglobulin A Nephropathy (IgAN) in the US

Immunoglobulin A Nephropathy
Novartis Pharmaceuticals300 enrolled1 locationNCT06952426
Recruiting
Phase 4

Multicentre Clinical Study to Evaluate the Effect of Personalized Therapy on Patients With Immunoglobulin A Nephropathy.

GlomerulonephritisImmunoglobulin A Nephropathy
Fondazione Schena878 enrolled2 locationsNCT04662723